glp-1 cardiovascular outcomes news 363. Agonists: Diving into the Data with Dr. Darren McGuire An Observational Study of Cardiovascular

3 When sitagliptin plus pioglitazone was compared with pioglitazone plus placebo, the most common side effects reported included upper respiratory tract infection (6.3% vs

Pharmaceutical firms are conducting intensive R&D for introducing new generation oral GLP-1 receptor agonists in the market

Our injectors use a technique that is gentle and efficient, so any momentary discomfort fades immediately once the injection is complete

Senile osteoporosis has become a major global public health problem with an increasing number of fractures, disabilities and high socio-economic costs

QT prolongation through hERG K + channel blockade: current knowledge and strategies for the early prediction during drug development

Although demographic and clinical predictors of discontinuation have been assessed, 74 the underlying reasons for discontinuation remain poorly quantified